Voyager Therapeutics Inc. Insider Trading

VYGR

Last 12 months

Insiders sold 298K and bought nothing on the open market.

74% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Sep 2018.

Net open-market

−298K

0 buys · 11 sales

Under a 10b5-1 plan

74%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Sep 2018

Sep 12, 2018

Get an email when VYGR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Apr 2	Alfred Sandrock President and CEO	Sold10b5-1 plan	11,511	$3.87	45K	2.4%	Form 4
Feb 24	Robin Swartz COO & Cbo	Sold10b5-1 plan	6,458	$3.77	24K	3.1%	Form 4
Feb 24	Alfred Sandrock President and CEO	Sold10b5-1 plan	14,197	$3.79	54K	2.8%	Form 4
Feb 24	Nathan D. Jorgensen Chief Financial Officer	Sold10b5-1 plan	4,668	$3.77	18K	3.0%	Form 4
Feb 24	Todd Alfred Carter Chief Scientific Officer	Sold10b5-1 plan	4,174	$3.76	16K	2.8%	Form 4
Feb 18	Robin Swartz COO & Cbo	Sold10b5-1 plan	3,882	$3.44	13K	1.8%	Form 4
Feb 18	Todd Alfred Carter Chief Scientific Officer	Sold10b5-1 plan	3,301	$3.44	11K	2.2%	Form 4
Feb 18	Alfred Sandrock President and CEO	Sold10b5-1 plan	11,732	$3.41	40K	2.3%	Form 4
Feb 10	Robin Swartz COO & Cbo	SoldNo plan	4,569	$3.85	18K	2.1%	Form 4
Feb 10	Alfred Sandrock President and CEO	SoldNo plan	12,192	$3.78	46K	2.3%	Form 4
Feb 10	Todd Alfred Carter Chief Scientific Officer	SoldNo plan	3,525	$3.85	14K	2.2%	Form 4
Oct 3, 2025	Nathan D. Jorgensen Chief Financial Officer	Sold10b5-1 plan	7,666	$4.78	37K	5.8%	Form 4
Aug 18, 2025	Toby Ferguson Chief Medical Officer	SoldNo plan	19,000	$3.73	71K	12%	Form 4
Apr 2, 2025	Toby Ferguson Chief Medical Officer	SoldNo plan	10,086	$3.43	35K	6.0%	Form 4
Apr 2, 2025	Alfred Sandrock President and CEO	SoldNo plan	10,885	$3.43	37K	2.5%	Form 4
Feb 20, 2025	Todd Alfred Carter Chief Scientific Officer	SoldNo plan	3,305	$4.26	14K	2.6%	Form 4
Feb 20, 2025	Alfred Sandrock President and CEO	SoldNo plan	11,702	$4.24	50K	2.6%	Form 4
Feb 20, 2025	Robin Swartz COO & Cbo	SoldNo plan	3,894	$4.25	17K	2.2%	Form 4
Feb 11, 2025	Todd Alfred Carter Chief Scientific Officer	SoldNo plan	5,413	$4.45	24K	6.3%	Form 4
Feb 11, 2025	Robin Swartz COO & Cbo	SoldNo plan	6,950	$4.45	31K	6.4%	Form 4
Feb 11, 2025	Alfred Sandrock President & CEO	SoldNo plan	16,644	$4.45	74K	5.1%	Form 4
Feb 11, 2025	Sandell Jacquelyn Fahey Chief Legal Officer	SoldNo plan	4,358	$4.45	19K	5.1%	Form 4
Jan 14, 2025	Robin Swartz COO & Cbo	SoldNo plan	3,087	$5.09	16K	2.7%	Form 4
Jan 14, 2025	Todd Alfred Carter Chief Scientific Officer	SoldNo plan	1,191	$5.13	6K	1.4%	Form 4
Dec 23, 2024	Robin Swartz Coo&cbo	SoldNo plan	6,500	$5.65	37K	5.5%	Form 4

Apr 210b5-1 plan
Alfred Sandrock
President and CEO · sold 11,511 at $3.87
45K
2.4% of stake
Feb 2410b5-1 plan
Robin Swartz
COO & Cbo · sold 6,458 at $3.77
24K
3.1% of stake
Feb 2410b5-1 plan
Alfred Sandrock
President and CEO · sold 14,197 at $3.79
54K
2.8% of stake
Feb 2410b5-1 plan
Nathan D. Jorgensen
Chief Financial Officer · sold 4,668 at $3.77
18K
3.0% of stake
Feb 2410b5-1 plan
Todd Alfred Carter
Chief Scientific Officer · sold 4,174 at $3.76
16K
2.8% of stake
Feb 1810b5-1 plan
Robin Swartz
COO & Cbo · sold 3,882 at $3.44
13K
1.8% of stake
Feb 1810b5-1 plan
Todd Alfred Carter
Chief Scientific Officer · sold 3,301 at $3.44
11K
2.2% of stake
Feb 1810b5-1 plan
Alfred Sandrock
President and CEO · sold 11,732 at $3.41
40K
2.3% of stake
Feb 10No plan
Robin Swartz
COO & Cbo · sold 4,569 at $3.85
18K
2.1% of stake
Feb 10No plan
Alfred Sandrock
President and CEO · sold 12,192 at $3.78
46K
2.3% of stake
Feb 10No plan
Todd Alfred Carter
Chief Scientific Officer · sold 3,525 at $3.85
14K
2.2% of stake
Oct 3, 202510b5-1 plan
Nathan D. Jorgensen
Chief Financial Officer · sold 7,666 at $4.78
37K
5.8% of stake
Aug 18, 2025No plan
Toby Ferguson
Chief Medical Officer · sold 19,000 at $3.73
71K
12% of stake
Apr 2, 2025No plan
Toby Ferguson
Chief Medical Officer · sold 10,086 at $3.43
35K
6.0% of stake
Apr 2, 2025No plan
Alfred Sandrock
President and CEO · sold 10,885 at $3.43
37K
2.5% of stake
Feb 20, 2025No plan
Todd Alfred Carter
Chief Scientific Officer · sold 3,305 at $4.26
14K
2.6% of stake
Feb 20, 2025No plan
Alfred Sandrock
President and CEO · sold 11,702 at $4.24
50K
2.6% of stake
Feb 20, 2025No plan
Robin Swartz
COO & Cbo · sold 3,894 at $4.25
17K
2.2% of stake
Feb 11, 2025No plan
Todd Alfred Carter
Chief Scientific Officer · sold 5,413 at $4.45
24K
6.3% of stake
Feb 11, 2025No plan
Robin Swartz
COO & Cbo · sold 6,950 at $4.45
31K
6.4% of stake
Feb 11, 2025No plan
Alfred Sandrock
President & CEO · sold 16,644 at $4.45
74K
5.1% of stake
Feb 11, 2025No plan
Sandell Jacquelyn Fahey
Chief Legal Officer · sold 4,358 at $4.45
19K
5.1% of stake
Jan 14, 2025No plan
Robin Swartz
COO & Cbo · sold 3,087 at $5.09
16K
2.7% of stake
Jan 14, 2025No plan
Todd Alfred Carter
Chief Scientific Officer · sold 1,191 at $5.13
6K
1.4% of stake
Dec 23, 2024No plan
Robin Swartz
Coo&cbo · sold 6,500 at $5.65
37K
5.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch VYGR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with VYGR

CompareIntrinsic value

SGMOSangamo Therapeutics Inc.

$0.12-0.20%10

CCCCC4 Therapeutics Inc.

$3.12-2.80%33

SCLXScilex Holding Company

$1.83-1.08%0

GLUEMonte Rosa Therapeutics, Inc.

$10.82+3.94%10

PTHSPelthos Therapeutics Inc.

$10.15-5.84%0

MGXMetagenomi, Inc.

$0.79+3.95%10

DTILPrecision Biosciences Inc.

$7.89+13.20%48

STROSutro Biopharma, Inc.

$9.94+4.52%10

Held by ETFs

VYGR is in 9 US ETFs. The largest of them, with VYGR's weight in each:

Spot a number that looks wrong? Check it in VYGR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing VYGR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.